Therapeutic Sequencing Beyond Second Line in Progressive Small Bowel Neuroendocrine Tumor

This segment addresses treatment planning after progression on second line therapy in progressive small bowel neuroendocrine tumor. Dr Lieu outlines common sequencing strategies following peptide receptor radionuclide therapy or targeted oral agents and emphasizes the need for ongoing reassessment at each decision point. Disease behavior, symptom evolution, and cumulative toxicity are discussed as key drivers of subsequent choices.

Options in later lines include alternative systemic therapies, enrollment in clinical trials, and supportive care focused strategies depending on patient goals and clinical context. The speakers highlight that sequencing in progressive small bowel neuroendocrine tumor is rarely linear. Patterns of progression, whether focal or diffuse, may influence the selection of next interventions.

Clinical trials are emphasized as an important component of care, offering access to novel agents while contributing to advancement of the field. Dr Lieu discusses how and when to introduce trial discussions and how to align research participation with patient preferences.

This segment reinforces flexibility and shared decision making as central principles in later line management. By integrating clinical judgment, evolving evidence, and patient priorities, clinicians can continue to provide meaningful care throughout the disease course.